Two Stocks in Concentration: Bonanza Creek Energy, Inc. (NYSE:BCEI), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

earning reaction history, nasdaq, nyse

Bonanza Creek Energy, Inc. (NYSE:BCEI)

The company announced its last quarter financial performance results on 11/10/2016. Bonanza Creek Energy, Inc. (NYSE:BCEI) belongs to Oils-Energy sector that surged 3% in value when last trading session closed at $1.03. The company has a market capitalization of $118.03 Million. The company’s stock has a Return on Assets (ROA) of -54.2 percent, a Return on Equity (ROE) of -489 percent and Return on Investment (ROI) of -68.7 percent. The company reached its 52-Week high of $5.5 on Jan 4, 2016 and 52-Week low of $0.6 on Aug 2, 2016.

Earnings per share (ttm) for Bonanza Creek Energy, Inc. (NYSE:BCEI) according to Finviz Data is $-14.37.

The growth estimate for Bonanza Creek Energy, Inc. (NYSE:BCEI) for the current quarter is -58.8 percent. The projected growth estimate for the next quarter is 32.6 percent. The company’s stock has grown by 8.7 percent in the past 5 years. For the next 5 years, the company is expected to grow by 15 percent.

This company was Upgrade by Stifel on 29-Sep-16  to Hold.

The 7 analysts offering 12-month price forecasts for Bonanza Creek Energy Inc have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 0.25. The median estimate represents a -2.91% decrease from the last price of 1.03.

Financial History:

Following Earnings result, share price were UP 11 times out of last 18 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  0 times and missed earnings  8  times.

The consensus recommendation for Bonanza Creek Energy, Inc. (NYSE:BCEI) is 3.57. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3.63. In comparison, the consensus recommendation 60 days ago was at 3.59, and 90 days ago was at 3.56 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Bonanza Creek Energy, Inc. to have earnings per share of $-0.27.

Revenue is expected to range from 43.64 Million to 50.89 Million with an average of 47.49 Million.

Company Profile:

Bonanza Creek Energy, Inc. is engaged in the acquisition, exploration and development of onshore oil and natural gas properties in the United States. The Company’s core operating areas are the DJ Basin in Colorado and the Cotton Valley formation in southern Arkansas. Bonanza Creek Energy, Inc. is based in Denver, Colorado.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP):

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) belongs to Medical sector closed its last session with a loss of -10.49 percent and closed its previous trading session at $0.47. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-2.24. The company has the Market capitalization of $19.13 Million. The company’s stock has a Return on Assets (ROA) of -125.5 percent, a Return on Equity (ROE) of -143.4 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $7.95 on Jan 5, 2016 and 52-Week low of $0.35 on Nov 28, 2016.

This company was Downgrade by ROTH Capital on 7-Sep-16 to Neutral.

The 1 analysts offering 12-month price forecasts for Tonix Pharmaceuticals Holding Corp have a median target of 0.60, with a high estimate of 0.60 and a low estimate of 0.60. The median estimate represents a +26.74% increase from the last price of 0.47.

Financial History:

Following Earnings result, share price were DOWN 2 times out of last 3 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 16% percent of times. It has met expectations  1 times and missed earnings  9  times.

The consensus recommendation for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is 3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Tonix Pharmaceuticals Holding Corp. to have earnings per share of $-0.2.

Company Profile:

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.